These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 25408207)

  • 1. Peripheral α-defensins 1 and 2 are elevated in Alzheimer's disease.
    Watt AD; Perez KA; Ang CS; O'Donnell P; Rembach A; Pertile KK; Rumble RL; Trounson BO; Fowler CJ; Faux NG; Masters CL; Villemagne VL; Barnham KJ
    J Alzheimers Dis; 2015; 44(4):1131-43. PubMed ID: 25408207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increasing the predictive accuracy of amyloid-β blood-borne biomarkers in Alzheimer's disease.
    Watt AD; Perez KA; Faux NG; Pike KE; Rowe CC; Bourgeat P; Salvado O; Masters CL; Villemagne VL; Barnham KJ
    J Alzheimers Dis; 2011; 24(1):47-59. PubMed ID: 21157020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amyloid beta peptides in cerebrospinal fluid as profiled with surface enhanced laser desorption/ionization time-of-flight mass spectrometry: evidence of novel biomarkers in Alzheimer's disease.
    Lewczuk P; Esselmann H; Groemer TW; Bibl M; Maler JM; Steinacker P; Otto M; Kornhuber J; Wiltfang J
    Biol Psychiatry; 2004 Mar; 55(5):524-30. PubMed ID: 15023581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relevance of defensin β-2 and α defensins (HNP1-3) in Alzheimer's disease.
    Szekeres M; Ivitz E; Datki Z; Kálmán J; Pákáski M; Várhelyi ZP; Klivényi P; Zadori D; Somogyvári F; Szolnoki Z; Vécsei L; Mándi Y
    Psychiatry Res; 2016 May; 239():342-5. PubMed ID: 27082275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma amyloid-beta as a biomarker in Alzheimer's disease: the AIBL study of aging.
    Lui JK; Laws SM; Li QX; Villemagne VL; Ames D; Brown B; Bush AI; De Ruyck K; Dromey J; Ellis KA; Faux NG; Foster J; Fowler C; Gupta V; Hudson P; Laughton K; Masters CL; Pertile K; Rembach A; Rimajova M; Rodrigues M; Rowe CC; Rumble R; Szoeke C; Taddei K; Taddei T; Trounson B; Ward V; Martins RN; AIBL Research Group
    J Alzheimers Dis; 2010; 20(4):1233-42. PubMed ID: 20413897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer's disease patients and controls.
    Martínez-Morillo E; Hansson O; Atagi Y; Bu G; Minthon L; Diamandis EP; Nielsen HM
    Acta Neuropathol; 2014 May; 127(5):633-43. PubMed ID: 24633805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The amyloid-β degradation pattern in plasma--a possible tool for clinical trials in Alzheimer's disease.
    Pannee J; Törnqvist U; Westerlund A; Ingelsson M; Lannfelt L; Brinkmalm G; Persson R; Gobom J; Svensson J; Johansson P; Zetterberg H; Blennow K; Portelius E
    Neurosci Lett; 2014 Jun; 573():7-12. PubMed ID: 24796810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
    Sunderland T; Mirza N; Putnam KT; Linker G; Bhupali D; Durham R; Soares H; Kimmel L; Friedman D; Bergeson J; Csako G; Levy JA; Bartko JJ; Cohen RM
    Biol Psychiatry; 2004 Nov; 56(9):670-6. PubMed ID: 15522251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apolipoprotein C-III is an amyloid-β-binding protein and an early marker for Alzheimer's disease.
    Shih YH; Tsai KJ; Lee CW; Shiesh SC; Chen WT; Pai MC; Kuo YM
    J Alzheimers Dis; 2014; 41(3):855-65. PubMed ID: 24685634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brain amyloid-beta fragment signatures in pathological ageing and Alzheimer's disease by hybrid immunoprecipitation mass spectrometry.
    Portelius E; Lashley T; Westerlund A; Persson R; Fox NC; Blennow K; Revesz T; Zetterberg H
    Neurodegener Dis; 2015; 15(1):50-7. PubMed ID: 25591542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma biomarkers of Alzheimer's disease.
    Kawarabayashi T; Shoji M
    Curr Opin Psychiatry; 2008 May; 21(3):260-7. PubMed ID: 18382225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of omega-3 fatty acids on inflammatory markers in cerebrospinal fluid and plasma in Alzheimer's disease: the OmegAD study.
    Freund-Levi Y; Hjorth E; Lindberg C; Cederholm T; Faxen-Irving G; Vedin I; Palmblad J; Wahlund LO; Schultzberg M; Basun H; Eriksdotter Jönhagen M
    Dement Geriatr Cogn Disord; 2009; 27(5):481-90. PubMed ID: 19439966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amyloid beta1-40 quantification in CSF: comparison between chromatographic and immunochemical methods.
    Simonsen AH; Hansson SF; Ruetschi U; McGuire J; Podust VN; Davies HA; Mehta P; Waldemar G; Zetterberg H; Andreasen N; Wallin A; Blennow K
    Dement Geriatr Cogn Disord; 2007; 23(4):246-50. PubMed ID: 17310122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enabling a multidisciplinary approach to the study of ageing and Alzheimer's disease: an update from the Australian Imaging Biomarkers and Lifestyle (AIBL) study.
    Ellis KA; Rainey-Smith SR; Rembach A; Macaulay SL; Villemagne VL;
    Int Rev Psychiatry; 2013 Dec; 25(6):699-710. PubMed ID: 24423223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of novel APP/Abeta isoforms in human cerebrospinal fluid.
    Portelius E; Brinkmalm G; Tran AJ; Zetterberg H; Westman-Brinkmalm A; Blennow K
    Neurodegener Dis; 2009; 6(3):87-94. PubMed ID: 19229112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced levels of amyloid-beta-binding proteins in cerebrospinal fluid from Alzheimer's disease patients.
    Hansson SF; Andréasson U; Wall M; Skoog I; Andreasen N; Wallin A; Zetterberg H; Blennow K
    J Alzheimers Dis; 2009; 16(2):389-97. PubMed ID: 19221428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
    Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
    Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Alzheimer's disease-associated risk loci on cerebrospinal fluid biomarkers and disease progression: a polygenic risk score approach.
    Martiskainen H; Helisalmi S; Viswanathan J; Kurki M; Hall A; Herukka SK; Sarajärvi T; Natunen T; Kurkinen KM; Huovinen J; Mäkinen P; Laitinen M; Koivisto AM; Mattila KM; Lehtimäki T; Remes AM; Leinonen V; Haapasalo A; Soininen H; Hiltunen M
    J Alzheimers Dis; 2015; 43(2):565-73. PubMed ID: 25096612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma and cerebrospinal fluid alpha1-antichymotrypsin levels in Alzheimer's disease: correlation with cognitive impairment.
    DeKosky ST; Ikonomovic MD; Wang X; Farlow M; Wisniewski S; Lopez OL; Becker JT; Saxton J; Klunk WE; Sweet R; Kaufer DI; Kamboh MI
    Ann Neurol; 2003 Jan; 53(1):81-90. PubMed ID: 12509851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study.
    Villemagne VL; Burnham S; Bourgeat P; Brown B; Ellis KA; Salvado O; Szoeke C; Macaulay SL; Martins R; Maruff P; Ames D; Rowe CC; Masters CL;
    Lancet Neurol; 2013 Apr; 12(4):357-67. PubMed ID: 23477989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.